Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

Scotts Miracle-Gro outlines $1B sales and $1B EBITDA growth targets through 2030 as it launches $500M share repurchase and divests Hawthorne

View original at seekingalpha.com
Scotts Miracle-Gro outlines $1B sales and $1B EBITDA growth targets through 2030 as it launches $500M share repurchase and divests Hawthorne Earnings Call Insights: Scotts Miracle-Gro Company (SMG) Q1 2026 MANAGEMENT VIEW * CEO James Hagedorn announced a strategic shift toward long-term value creation, emphasizing "str…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Product and channel innovation, e-commerce gains, branded product growth, and M&A are key drivers for growth targets

    80% confidence
  • Share repurchase program will be disciplined, emphasizing leverage targets and capital allocation priorities

    80% confidence
  • Supply chain priorities include a little bit of everything everywhere, automation in distribution centers, and tech transformation

    80% confidence
  • Company will leverage free cash flow along with access to revolver to pay off debt maturities later this summer

    80% confidence
  • Making strong and consistent progress as company focuses on actions that drive long-term value creation, off to good start and optimistic for the year

    80% confidence
  • Marketing and consumer activation spend approaching $1 billion annually

    80% confidence
  • M&A will contribute about 1% annually to growth out into 2027 and beyond

    80% confidence
  • Leadership direction will be less focused on quarterly performance and more focused on long-term milestones

    80% confidence
  • Good probability that company will outperform fiscal 2026 guidance

    80% confidence
  • Company is leaning into e-commerce and saw double-digit growth in e-commerce

    80% confidence
  • Strategic shift toward long-term value creation, emphasizing strategies to drive more value for shareholders with new longer-term financial priorities through 2030

    80% confidence
  • E-commerce business can be huge with margin delta less than 5 percentage points and getting better every quarter

    80% confidence
  • Classifying Hawthorne as discontinued operation is having immediate positive effect, contributing to 40 basis point improvement in gross margin and strengthening balance sheet while eliminating cannabis sector volatility impact on share price

    80% confidence
  • Company feels comfortable navigating to outperform 32% gross margin target, built incentive plan approved by Board where guidance numbers would not pay out at 100%

    80% confidence
  • Ultimate goal is to get share count to around 40 million shares

    80% confidence
  • Three-stage execution plan: hitting fiscal 2026 guidance, achieving midterm priorities through 2027, and delivering on new long-term goal of $1 billion in top line sales growth and $1 billion in EBITDA

    80% confidence
  • Potential shareholder return in excess of 50% with share price well north of $100 upon full execution of long-term objectives

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com